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Abstract
The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limited by its toxicity and the
development of multidrug resistance (MDR), the latter mainly induced by high expression of efflux pumps (e.g., P-
glycoprotein [P-gp]). Therefore, the search for alternative therapies, which sensitize these tumors to chemotherapy while
maintaining a low toxicity profile, is a rational approach. We assessed efficacy and molecular mechanisms involved in the
antiproliferative effects of the tyrosine kinase inhibitors, nilotinib and imatinib, as single agents or in combination with DXR,
in human synovial sarcoma SW982 and leiomyosarcoma SK-UT-1 cells. As single compound nilotinib (1–10 mM) was more
potent than imatinib inhibiting the growth of SK-UT-1 and SW982 cells by 33.5–59.6%, respectively. Importantly, only
nilotinib synergized the antitumoral effect of DXR (0.05–0.5 mM) by at least 2-fold, which clearly surpassed the mere sum of
effects according to isobolographic analysis. Moreover, nilotinib in combination with DXR had a sustained effect on cell
number (270.365.8%) even 12 days after withdrawal of drugs compared to DXR alone. On the molecular level, only
nilotinib fully blocked FBS-induced ERK1 and p38 MAPK activation, hence, reducing basal and DXR-induced up-regulation of
P-gp levels. Moreover, efflux activity of the MDR-related proteins P-gp and MRP-1 was inhibited, altogether resulting in
intracellular DXR retention. In high-risk STS tumors 53.8% and 15.4% were positive for P-gp and MRP-1 expression,
respectively, with high incidence of P-gp in synovial sarcoma (72.7%). In summary, nilotinib exhibits antiproliferative effects
on cellular models of STS and sensitizes them to DXR by reverting DXR-induced P-gp-mediated MDR and inhibiting MRP-1
activity, leading to a synergistic effect with potential for clinical treatment.
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Introduction
Sarcomas are a heterogeneous group of malignant mesenchy-
mal tumors. Within this group, soft tissue sarcomas (STS) are
cancers of muscle, fat, fibrous or other supporting tissues of the
body. Although the most common treatment is surgical removal of
the entire tumor, doxorubicin (DXR)-based chemotherapy has
been the current treatment for patients with locally advanced
inoperable or metastatic disease [1]. However, the clinical
effectiveness of DXR is limited by severe toxicity and the
development of multidrug resistance (MDR), the latter mainly
involving high cellular expression of ATP-binding cassette (ABC)
transporters in the plasma membrane, including P-glycoprotein (P-
gp) and multidrug resistance-related protein 1 (MRP-1) [2,3].
These proteins are ATP-dependent pumps that carry xenobiotic
agents, such as the antineoplastic compound DXR, out of the cells,
thereby reducing its antitumoral effect. Accordingly, the search for
combination therapies, which are able to counteract such
resistance mechanism in cancer cells without increasing general
toxicity, is a rational clinical approach.
Anticancer therapy based on molecular targeting comprises
selective inhibition of specific tyrosine kinases (TKs), which play a
crucial role in tumor growth or progression [4]. Therefore, TK
inhibitors have become a promising therapeutic option for
treatment of cancer types whose molecular pathogenesis implicates
the overexpression or activation of various TKs (e.g., BCR/ABL)
or TK receptors (e.g., c-KIT, PDGFR and EGFR, among others)
[5]. Usually, inhibition of oncogenic TK activity leads to down-
regulation of several downstream signaling pathways, including
mitogen-activated protein kinase (MAPK) cascades and phospha-
tidylinositol 39-kinase (PI3K)/AKT pathway, consequently re-
pressing proliferation, invasion and survival of cancer cells.
Accordingly, the TK inhibitor imatinib mesylate (STI571;
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chronic myeloid leukaemia (CML) harbouring BCR/ABL trans-
location [6] or for those with advanced gastrointestinal stromal
tumor (GIST) showing specific mutations in c-KIT or PDGFRa
genes, which activate these TKs [7]. Despite the fact that imatinib
initially improves dramatically the outcome of these patients, its
beneficial effect is limited by intrinsic and acquired drug
resistance, which prevails in most of the patients and finally leads
to relapse or interruption of treatment [8,9]. These findings
promoted the development of a second generation of TK
inhibitors, such as sunitinib (SU11248, Sutent; Pfizer) [10] and
nilotinib (AMN107, Tasigna, Novartis) [11]. Nilotinib has been
reported to inhibit BCR/ABL kinase more potently than imatinib
being at least similarly effective concerning c-KIT and PDGFR
kinases [12]. Nilotinib differs from imatinib regarding its cellular
transport, leading to higher intracellular levels (5 to 10-fold) of this
agent [13]. In parallel, nilotinib still exhibited antitumoral efficacy
in patients with CML [14] and GIST, who were resistant to
imatinib or sunitinib [15]. Very recently it has been demonstrated
that nilotinib has also potential to reverse MDR by inhibiting the
activity of P-gp and ABCG2 transporters in human embryonic
kidney (HEK) 293 cells that exogenously overexpress these efflux
pumps [16].
Although some studies have evaluated the effectiveness of
imatinib and sunitinib in STS other than GIST [17,18] only little
is known regarding the effectiveness of nilotinib and whether a
combination of TK inhibitors with conventional chemotherapy
may improve treatment outcome for this type of solid tumors. Our
study compares the effectiveness and molecular mechanisms
involved in the antiproliferative effects of the TK inhibitors,
nilotinib and imatinib, as individual therapeutic agents or in
combination with DXR, in human cell lines of STS, being
susceptible to development of drug resistance.
Materials and Methods
Cell culture and treatments
The human synovial sarcoma SW982 and leiomyosarcoma SK-
UT-1 cell lines were obtained from the American Type Culture
Collection (Manassas, VA). Synovial sarcoma cells were grown in
Leibovitz’s L-15 medium (Invitrogen S.A, Barcelona, Spain),
whereas leiomyosarcoma cells were cultured in DMEM medium
(LabClinics S.A, Barcelona, Spain) supplemented with MEM-non
essential aminoacids (dilution 1:100) and 1 mM sodium pyruvate.
Both media contained 2 mM L-glutamine and were supplemented
with 10% (v/v) fetal bovine serum, 100 units/ml penicillin and
100 mg/ml streptomycin. Tissue culture supplements were all
purchased from Sigma-Aldrich (Madrid, Spain). When the cells
reached 60–70% confluence, vehicle (DMSO), nilotinib (NVP-
AMN107-AA), imatinib mesylate or doxorubicin (DXR) as single
agents or their combinations were added to the medium for 24–
96 h. Nilotinib and imatinib were kindly provided by Novartis
Pharma AG (Basel, Switzerland). DXR was purchased from
Sigma-Aldrich. Stock solutions of nilotinib and imatinib were
prepared at 10 mM in dimethylsulfoxide (DMSO) or in water in
the case of DXR.
Cell viability
Synovial sarcoma and leiomyosarcoma cells were plated in 96-
well plates at a density of 11610
3 or 8610
3 cells per well in 200 ml
of their respective growth medium, and grown for 24 h. To test
the effectiveness of DXR and TK inhibitors on cell growth, cells
were exposed to increasing concentrations of DXR, nilotinib or
imatinib (0.05–90 mM) for 72 h. The compound concentration
resulting in 50% inhibition of cell viability (IC50) was determined
using GraphPad software. To determine whether nilotinib and
imatinib would increase sensitivity of these cell lines to DXR, cells
were treated with varying concentrations of TK inhibitors (range
0.1–40 mM) with DXR (0.05–0.5 mM) or without it for 72 h.
Synovial sarcoma cells were treated simultaneously with DXR and
TK inhibitors, whereas leiomyosarcoma cells were pre-treated
with vehicle or TK inhibitor for 24 h, and DXR was then added
to the corresponding wells and treatment continued for another
48 h. These experimental conditions appeared to be the most
effective combination in a previous study. After 72 h, the viability
of the cells was measured using the methylthiazoletetrazolium
(MTT) method. Absorbance was measured at 570 (for SW982
cells) and 590/650 nm (for SK-UT-1 cells) on an ELISA plate
reader (Asys Hitech GmbH, Austria). The mean percentage of cell
survival relative to that of vehicle-treated cells was estimated from
data of three individual experiments performed by triplicate.
Isobolographic analysis
The effects of the combination of nilotinib with DXR in
synovial sarcoma cell growth were analyzed by Loewe’s isobolo-
graphic analysis revised by Steel and Peckman [19], which
distinguishes three types of interactions: pure additivity, synergy
and antagonism. In this model, the combination index (CI) is
described by CI=dA/DA+dB/DB, where dA and dB are the
concentration of drug A and B given in a combination of two
drugs and DA and DB are the concentration of drug A and B
yielding the same effect level, when administered alone, as the
mixture. Combinations with CI.1 are considered as antagonistic,
those with CI=1 are additive, and those with CI,1 are
synergistic. If synergy exists, then a lower concentration of dA
and/or dB would be required to achieve the same effects of the
theoretical dosages for additivity [20]. In our studies CI values for
each condition were calculated using the IC50 of cell growth as the
isoeffective point and these values were determined by plotting the
results obtained in the MTT assay in a Hill Curve. The
isobolograms were constructed by plotting the IC50 of nilotinib
on the Y-axis and the IC50 of DXR on the X-axis, being the line
that connects these two points the line of additivity.
Cell proliferation assays
To study the effect of the withdrawal of nilotinib, DXR or
nilotinib plus DXR on cell proliferation, leiomyosarcoma cells
were pre-treated with vehicle or nilotinib for 24 h, and DXR was
then added to the corresponding wells and treatment continued
for another 72 h. After treatment, cells were recovered, diluted
and reseeded at a density of 1.8610
4 cell/well with culture
medium without any further compounds. After 12 days of cell
culture, cells were counted using a hemocytometer.
Cell cycle analysis and apoptosis
The apoptotic index and analysis of the cell cycle were
performed on STS cells by flow cytometry as described previously
[21]. Cell populations in the different phases of cell cycle (sub-G1
(cell death), G0/G1, S/G2/M peaks) were determined based on
their DNA content in a Beckman Coulter Epics XL flow
cytometer. Cellular apoptosis was also determined by assessment
of the cleavage of caspase 3, caspase 8 and PARP by immunoblot
analysis and measurement of caspases 3 and 7 activities by means
of the luminometric Caspase-Glo 3/7 assay (Promega, Barcelon,
Spain) according to the manufacturer’s instructions, using a
Synergy HT multidetection microplate reader (Bio-Tek, Winooski,
VT, USA).
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apoptosis in synovial sarcoma SW982 cells. A) Antiproliferative effect of nilotinib as single compound or combined with DXR. Synovial sarcoma
cells were treated with vehicle or nilotinib (0.1–40 mM) alone or combined simultaneously with DXR (0.1, 0.3 and 0.5 mM) for 72 h. Each value
represents mean 6 SEM of four individual experiments performed in triplicate. B) Subsequent isobolographic analyses were performed as described
in the Material and Methods section. Drug combination was synergistic at all concentrations (CI,1), as shown in the isobologram. C) Apoptotic effect
of nilotinib as single compound or combined with DXR (0.1 mM) for 72 h. Upper panels show the immunoreactive bands of procaspase 3, cleaved
caspase 3 and PARP fragmentation in representative immunoblots. DNA content of cells was measured by flow cytometry. Columns show percentage
of apoptotic cells in the absence (vehicle, V) or presence of DXR and nilotinib as single compounds or combined (DXR+nilotinib). Each column
represents mean 6 SEM of four independent experiments.
***P,0.001 versus DXR-treated cells. D) Antiproliferative effect of imatinib (0.5–10 mM) as
single compound or combined with DXR (0.1 mM) for 72 h. Each column represents mean 6 SEM of three independent experiments.
doi:10.1371/journal.pone.0037735.g001
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Preparation of cell extracts and protein assays were performed
as described previously [21] with the following change: phospha-
tase inhibitor cocktails 1 and 2 (Sigma, Madrid) were added to the
ice-cold lysis buffer (dilution 1:100). Primary polyclonal antibodies
anti-poly ADP-ribose polymerase (anti-PARP) (116 and 89 KDa),
anti-caspase 3 (35 kDa), anti-cleaved caspase-3 (Asp175) (17–
19 kDa), anti-phospho-AKT (P-AKT) (Ser473; 60 kDa), anti-
AKT (60 kDa), anti-phospho p38 MAPK (P-p38 MAPK)
(Thr180/Tyr182; 38 kDa), anti-p38 MAPK (p38 MAPK)
(38 kDa), anti-phospho-p44/42 MAPK (P-ERK1/2) (Thr202/
Tyr204), anti-p44/42 MAPK (ERK1/2) and the monoclonal
antibodies anti-caspase 8 (full lenght 57 kDa; the cleaved
intermediate 43 and 41 kDa and the active fragment 18 kDa)
and anti-b-actin (42 kDa) were obtained from Cell Signaling
Technology (Danvers, MA). The monoclonal anti-MDR1 (P-gp)
(170 kDa) was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Antibodies were all diluted 1:1000. The
intensity of band immunoreactivity was analyzed by densitometry
with TotalLab software from Nonlinear dynamics (Amersham). To
assess the changes of phosphorylation or protein levels, the
intensity of each phosphorylated protein or protein band was
normalized against the intensity of the corresponding total protein
or b-actin band, respectively. This procedure was repeated at least
three times for each sample on different gels.
Quantification of intracellular doxorubicin
Synovial sarcoma cells were treated with vehicle (DMSO) or
DXR (1 mM) in the absence or presence of nilotinib (1–10 mM)
and imatinib (1–10 mM) for 24 h. Leiomyosarcoma cells were pre-
Figure 2. Combination of nilotinib, but not imatinib, with doxorubicin displayed a synergistic effect on apoptosis in
leiomyosarcoma SK-UT-1 cells. A, left, DNA content of cells was measured by flow cytometry. Representative histograms of vehicle-treated
(DMSO), DXR (0.05 mM)-treated, nilotinib (5 mM)-treated and pre-nilotinib 24 h+DXR-treated cells are shown. The fluorescence values used to
calculate the peak corresponding to the sub-G1 phase are indicated on each histogram. Right, Columns show percentage of apoptotic cells in the
absence (vehicle, V) or presence of DXR and nilotinib as single agents or combined (pre-Nilotinib+DXR). Each column represents mean 6 SEM of four
independent experiments.
**P,0.01 and
***P,0.001 versus DXR-treated cells. B) Antiproliferative effect of imatinib as single compound or combined
with DXR (0.05 mM) (pre-Imatinib+DXR) for 72 h. Each column represents mean 6 SEM of three independent experiments. C) Panels show the
immunoreactive bands of procaspase 8 and 3, cleaved caspase 8 and 3, and PARP fragmentation in representative immunoblots of leiomyosarcoma
cells treated as in A.
doi:10.1371/journal.pone.0037735.g002
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then added to the corresponding wells and treatment continued
for another 24 h. After this time, cells were harvested, washed and
resuspended in PBS at 37uC. Fluorescence attributable to
intracellular DXR was immediately measured by flow cytometry
(Beckman Coulter Epics XL flow cytometer).
Activity of P-glycoprotein and multidrug resistance-
associated protein 1
To examine the effect of TK inhibitors on P-glycoprotein (P-gp)
and multidrug resistance-associated protein 1 (MRP-1) function,
the fluorescent dyes rhodamine 123 (Rho-123) and 5(6)-carboxy-
fluorescein diacetate (CFDA) were used. Synovial sarcoma and
leiomyosarcoma cells were incubated with 0.5 and 0.05 mMo f
Rho-123 respectively, or with 0.5 mM of CFDA dissolved in
complete medium for 30 min at 37uC. After removing the
extracellular free dye, the cells were incubated in dye-free media
containing vehicle (DMSO), verapamil (10 mM), probenecid
(250 mM), nilotinib (1–10 mM) or imatinib (1–10 mM). The efflux
of Rho-123 and CFDA was analyzed at different time points (2 or
24 h) by flow cytometry (Beckman Coulter Epics XL flow
cytometer).
P-gp and MRP-1 immunohistochemistry in clinical
samples
P-gp and MRP-1 expression was retrospectively analyzed in a
subset of fifty two high-risk (grade III T2b N0 M0) localized STS
tumors of limbs or trunk wall, which derived from a total of three
hundred and twenty-eight patients enrolled in a randomized
clinical trial conducted by Italian (ISG) and Spanish sarcoma
groups (GEIS) focusing on adjuvant chemotherapy treatment [22].
These cases were enrolled prospectively in GEIS centers and each
center received approval of its corresponding IRB. In the case of
the Coordinating Center, the approval was given by the Ethical
Committee of Clinical Investigation of the Balearic Islands in
September 12th 2002. The main IP for Spain was Javier Martı ´n
Broto (medical oncologist). The Spanish Agency for Medicines and
Health Products released its approval by May 12th, 2003. Written
informed consent was obtained from all participants involved in
this clinical trial. Three-micrometer sections of paraffin tissue
blocks, fixed with 4% formaldehyde, were dewaxed in xylene,
washed with PBS and pre-trated with citrate buffer (pH 6). Before
staining the sections, endogenous peroxidase was blocked with 3%
hydrogen peroxide. Immunohistochemical staining for P-gp or
MRP-1 was performed incubating the sections with the monoclo-
nal antibodies against P-gp (anti-P-gp dilution 1:20) (SIG-38720
from Sigma, Covance, USA) or MRP-1 (QCRL-1 dilution 1:100)
(sc-18835 from Santa Cruz, USA) during 30 and 40 min,
respectively. After incubation immunodetection was performed
with EnVision FLEX (Dako, Glostrup, Denmark), employing
diaminobenzidine chromogen (DAB) as substrate. Sections were
counterstained with hematoxylin. Results were independently
analysed by two pathologists who evaluated P-gp and MRP-1
expression qualitatively: positive (.10% positive cells) or negative.
Tumor samples were available from all patients at the time of
diagnosis so that only endogenous P-gp or MRP-1 expression was
analyzed.
Data analysis
The results are expressed as mean 6 SEM. One-way analysis of
variance (ANOVA) followed by Bonferroni’s multiple comparison
test was used for statistical evaluations. Differences were consid-
ered statistically significant at P,0.05. All calculations were done
by GraphPad Software.
Results
Growth inhibition by DXR, nilotinib and imatinib as single
compounds was determined over a period of 72 h in synovial
sarcoma SW982 and leiomyosarcoma SK-UT-1 cells. The
average IC50 values for DXR and nilotinib in these cell lines
were 1.3060.07 mM and 0.1360.09 mM, and 7.5560.05 mM and
27.0460.05 mM, respectively. At 10 mM nilotinib inhibited the
growth of SK-UT-1 and SW982 cells by 33.5 and 59.6%, whereas
imatinib showed only a mild effect on cell viability (inhibition of
12.1–19.1%) at the clinically achievable concentration of 10 mM
[23] (Fig. 1D and 2B), with an IC50 of 26.4860.02 mM and
8960.02 mM, respectively.
We then investigated whether molecular targeted therapy
(nilotinib and imatinib) might improve cell susceptibility to
DXR, which is the standard drug in conventional chemotherapies
for STS. To reveal the type of interaction between nilotinib and
DXR concerning growth inhibition, an isobolographic analysis
was performed and the combination index (CI) determined (as
explained in Materials and Methods). Nilotinib (0.1–40 mM) and
DXR (0.1, 0.3 and 0.5 mM) applied simultaneously for 72 h were
highly synergistic in synovial sarcoma SW982 cells (with CI of
0.74, 0.49 and 0.58, respectively; Fig. 1A and B). Likewise,
combination of nilotinib (2.5–10 mM) with DXR (0.1 mM) resulted
in increased cell death, raising 2.060.35 and 4.560.79-fold the
apoptotic effect of nilotinib and DXR, respectively (Fig. 1C). This
synergism was also displayed by significant enhancements of
cleaved caspase 3 and PARP, which were evaluated by western-
blotting analysis (Fig. 1C, upper pannels), as well as enhancement
of caspase 3 and 7 activities. Activated caspase 3/7 increased from
10062.3% in vehicle-treated cells to 114.5616.5% (n=4;
P.0.05) in DXR-treated cells, 235.3612.2 (n=4; P,0.001) in
nilotinib (10 mM)-treated cells and 333.9634.2% (n=4; P,0.01
versus nilotinib- and P,0.001 versus DXR-treated cells,) in
Figure 3. Nilotinib plus doxorubicin-treated leiomyosarcoma
SK-UT-1 cells showed prolonged inhibition of cell growth after
drug withdrawal. Cells were pre-treated with vehicle or nilotinib for
24 h, and DXR (0.05 mM) was then added to the corresponding wells
and treatment continued for another 72 h. Cells were then recovered,
diluted and reseeded at a density of 1.8610
4 cell per well with culture
medium without any further compounds. After 12 days, cells were
counted using a hemocytometer. Values are mean 6 SEM of three
independent experiments.
*P,0.05 and
**P,0.01 versus DXR-treated
cells.
doi:10.1371/journal.pone.0037735.g003
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nilotinib 24 hours before DXR exposure (0.05 mM) was the most
effective combination sequence in leiomyosarcoma cells. In these
cells nilotinib also synergized with DXR regarding apoptosis
induction, although nilotinib did not induce apoptosis alone even
after 96 h of treatment (Fig. 2A and C). Addition of nilotinib (2.5–
10 mM) 24 h before DXR enhanced the apoptotic effect of a 72 h
DXR treatment, increasing 1.860.21, 1.860.29 and 2.260.17-
fold the level of DXR-induced cell death. Interestingly, further
studies of apoptotic events also indicated the involvement of
caspase 8, 3 and 7. Thus, in leiomyosarcoma cells combination
therapy enhanced DXR-induced cleavage of caspase 8, 3 and
PARP, which was evaluated by western-blotting analysis (Fig. 2C)
as well as DXR-induced caspase 3 and 7 activities (activated
caspase 3/7 increased from 10060.7% in vehicle-treated cells to
247.5615.0% (n=4; P,0.001) upon treatment with DXR and
342.1630.5% (n=4; P,0.001 versus DXR-treated cells),
383.965.4% (n=4; P,0.001 vs DXR-treated cells) and
412.9620.7% (n=4; P,0.001 versus DXR-treated cells) upon
treatment with pre-nilotinib (2.5, 5 and 10 mM) plus DXR,
respectively). In contrast, imatinib was not able to enhance the cell
growth inhibition caused by DXR in any of the experimental
settings (Fig. 1D and 2B).
Cell proliferation after withdrawal of compounds at the end of
treatment was studied to investigate whether the synergism
provoked by the combination of nilotinib with DXR was rapidly
reversible or maintained during prolonged time. Leiomyosarcoma
cells treated with nilotinib alone for 96 h showed increased cell
Figure 4. Nilotinib decreased fetal bovine serum-induced AKT activation and fully blocked ERK1/2 and p38 MAPK activation. Sub-
confluent synovial sarcoma SW982 cells were deprived of fetal bovine serum (FBS) for 4 h. Cells were then stimulated for 30 min with 10% FBS in the
absence (vehicle, V) or presence of imatinib (10 mM) or nilotinib (5 and 10 mM) as single compounds. Upper panels show representative immunoblots
of four independent experiments. Columns represent the phosphorylated ratio of AKT, ERK1/2 and p38 MAPK. Each column represents mean 6 SEM
of four independent experiments normalized to FBS-depleted cells (-FBS, taken as 100%).
*P,0.05;
**P,0.01 and
***P,0.001 versus vehicle-treated
cells stimulated with FBS.
doi:10.1371/journal.pone.0037735.g004
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whereas cells treated with DXR grew somewhat slower than
control cells (Fig. 3). In contrast, combination of nilotinib (5–
10 mM) with DXR significantly reduced by 46.963.9% and
70.365.8% cell number when compared to DXR treatment, even
12 days after the end of treatment (Fig. 3).
AKT and MAPK (ERK1/2 and p38 MAPK) are important
signal transduction proteins implicated in growth factor-induced
proliferation and survival of cancer cells in STS, especially in
synovial sarcoma. SW982 cells showed low Akt, ERK1/2 and p38
MAPK phosphorylation after FBS starvation (lane 1, Fig. 4), but a
high degree of activation when they were stimulated with 10%
FBS for 30 minutes (lane 2, Fig. 4). Nilotinib significantly
decreased FBS-induced phosphorylation of AKT, reaching a
maximal inhibition at 10 mM of 43.269.0% when compared to
vehicle-treated cells (Fig. 4). Furthermore, FBS-induced phos-
phorylation of ERK1 and p38 MAPK was fully blocked by
nilotinib. Imatinib (10 mM) only slightly inhibited FBS-induced
ERK-1 and p38 MAPK phosphorylation by 29.962.3% and
19.462.3%, respectively, and did not affect AKT activation when
compared to vehicle-treated cells. Total AKT, ERK1/2 and p38
MAPK levels remained unchanged (Fig. 4).
To address the question whether the improved sensitivity of
sarcoma cells to DXR induced by nilotinib might be associated
with increased accumulation of DXR in these cells, intracellular
DXR levels were evaluated in the presence or absence of nilotinib.
Nilotinib applied simultaneously with DXR (1 mM) augmented
DXR accumulation in SW982 cells after 24 h, raising its levels to
1.960.09- and 2.160.12-fold at a dose of 5 and 10 mM nilotinib,
respectively (Fig. 5). Similarly, nilotinib pre-treatment also
increased dose-dependently DXR accumulation in leiomyosarco-
ma cells by 1.460.02- and 1.660.18-fold, respectively (Fig. 5). In
contrast, imatinib even at the highest dose did not significantly
increase intracellular DXR in synovial sarcoma cells. Intracellular
fluorescence intensity in imatinib- or nilotinib-treated cells was not
different from vehicle-treated cells (data not shown). These results
indicate that nilotinib, but not imatinib, enhances intracellular
DXR accumulation.
The effect of nilotinib on the activity of the MDR-relevant efflux
pumps P-gp and MRP-1 was then evaluated using the fluorescent
dyes Rho-123 and 5-CFDA, which are known P-gp and MRP-1
substrates, respectively. In order to measure the efflux activity of P-
gp in SK-UT-1 cells a lower concentration of Rho-123 (0.05 mM
versus 0.5 mM) and a longer efflux time (24 h versus 2 h) than in
Figure 5. Nilotinib, but not imatinib, increased intracellular doxorubicin in human STS cells. Synovial sarcoma SW982 and
leiomyosarcoma SK-UT-1 cells were incubated with vehicle (DMSO) or DXR (1 mM) in the absence (vehicle, V) or presence of nilotinib (1–10 mM) or
imatinib (1–10 mM) as described in the Material and Methods section. After 24 h incubation, intracellular DXR was measured by its fluorescence
intensity with flow cytometry. Left, Median of intracellular DXR fluorescence in the absence (V) or presence of TK inhibitors normalized to vehicle-
treated cells (taken as 100%). Each column represents mean 6 SEM of seven independent experiments. Right, Representative flow cytometry analysis
of the intracellular DXR fluorescence detected with excitation at 488 nm and emission at 580 nm in both cell lines.
***P,0.001 versus DXR-treated
cells.
doi:10.1371/journal.pone.0037735.g005
Nilotinib Reverses P-Glycoprotein Resistance
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37735SW982 cells had to be used because of the lower expression of P-
gp protein in SK-UT-1 cells. Nilotinib (5–10 mM) increased the
intracellular retention of Rho-123 by 2.460.30- and 1.660.08-
fold in synovial sarcoma and leiomyosarcoma cells, respectively
(Fig. 6), presenting higher efficacy than the P-gp inhibitor
verapamil (10 mM) used as positive control. In a similar way,
nilotinib also increased intracellular 5-CFDA accumulation by
11.860.45 and 11.160.33-fold in the above cell lines, being also
more effective than the MRP-1 inhibitor probenecid (250 mM)
used as positive control (Fig. 7). In contrast, the maximal dose of
imatinib (10 mM) only slightly, but not significantly, increased
intracellular Rho-123 and 5-CFDA by 1.260.06% and 1.260.07
fold in synovial sarcoma cells and by 1.360.07 and 1.560.13 fold
in leiomyosarcoma cells, respectively (Fig. 6 and 7).
In addition, nilotinib (10 mM, 72 or 96 h) also down-regulated
cellular expression of P-gp by 55.168.9% when compared to
vehicle-treated cells (Fig. 8A). Importantly, incubation of synovial
sarcoma cells with DXR (0.1 mM, 72 h) provoked a significant
upregulation of P-gp levels (55.2621.0%), which is generally
considered as the central molecular mechanism of MDR in
response to DXR treatment and which was fully blocked by
nilotinib (Fig. 8A).
The fact that nilotinib eliminated FBS-induced p38 MAPK
phosphorylation (Fig. 4) and that inhibition of this kinase reduces
MDR in some human cancer cells by modulating P-gp expression
[24,25], suggested to analyze the effect of nilotinib and DXR on
p38 MAPK phosphorylation. As shown in Fig. 8B, treatment of
cells with DXR (0.1 mM, 72 h) increased p38 MAPK phosphor-
ylation by 80.7629.9% in synovial sarcoma cells when compared
to vehicle-treated cells, whereas nilotinib treatment (10 mM, 72 h)
strongly inhibited basal phosphorylation by 60.264.6%. When
administered simultaneously nilotinib completely blocked DXR-
induced activation of p38 MAPK (Fig. 8B).
Defining P-gp and MRP-1 as additional therapeutic targets of
nilotinib to enhance antitumoral efficacy of DXR in STS would
only be, if these proteins were expressed in the clinical context.
Thus, endogenous P-gp and MRP-1 expression was qualitatively
and retrospectively evaluated by immunochemistry in a subset of
52 high-risk advanced STS tumors of limbs or trunk wall obtained
from 328 patients enrolled in an international randomized trial
[22], and positive immunoreactivity for P-gp was observed in 28
cases (53.8) and for MRP-1 in 8 cases (15.4%) (Table 1).
Coexpression of both MDR-related proteins was found in 6
(11.5%) tumor samples. From the 11 and 4 cases of synovial
sarcoma and leiomyosarcoma, 8 (72.7%) and 4 (100%) tumor
Figure 6. Nilotinib inhibited P-gp activity in human STS cells. Intracellular Rho-123 fluorescence (0.5 or 0.05 mM) was estimated by flow
cytometry in synovial sarcoma SW982 cells after 2 h treatment or in leiomyosarcoma SK-UT-1 cells after 24 h treatment with vehicle (DMSO), imatinib
(1–10 mM), nilotinib (1–10 mM) or verapamil (10 mM). Left, Median of intracellular Rho-123 fluorescence in the absence (vehicle, V) or presence of TK
inhibitors normalized to vehicle-treated cells (taken as 100%). Each column represents mean 6 SEM of five independent experiments. Right,
Representative flow cytometry analysis of the intracellular Rho-123 fluorescence in the absence (vehicle) or presence of imatinib (10 mM) or nilotinib
(10 mM) detected with excitation at 488 nm and emission at 580 nm. T0 was the intracellular Rho-123 fluorescence measured at t=0.
*P,0.05 and
***P,0.001 versus vehicle-treated cells.
doi:10.1371/journal.pone.0037735.g006
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and 1 (25%) as MRP-1-positive ones, respectively (Table 1).
Discussion
TK inhibitors are small molecules, whose mechanism of action
is ATP-binding site blockade of specific TKs and TK receptors,
thereby suppressing downstream pathways linked to cell prolifer-
ation. In this context, the TK inhibitors imatinib and nilotinib are
able to inhibit the activity of the TK BCR-ABL as well as the
activity of the TK receptors KIT and PDGF, being nilotinib more
potent and selective against BCR-ABL1 [12]. In contrast to
classical chemotherapeutics both compounds were developed for a
defined molecular target and imatinib shows clinically impressive
results in patients with CML or advanced GIST, in which
overexpression or gain of function of one of the above mentioned
kinases leads to malignant cell growth [6,7]. More importantly,
nilotinib maintains antitumoral activity against the majority of
imatinib-resistant mutants, and has a better side-effect profile than
imatinib [14,26,27]. Although some gene array and immunohis-
tochemistry studies in tumor tissues of patients with STS have
revealed that certain TK receptors (e.g., KIT, PDGFb) are
overexpressed [28,29], at present it is still unclear whether TK
inhibitors as single agents or combined with conventional
chemotherapy are effective on cellular models of STS others than
GIST [30] and Ewing tumor cells [31].
Our study demonstrates that the novel TK inhibitor nilotinib
exhibits higher antiproliferative activity than imatinib in two
human STS cell lines, whereby synovial sarcoma SW982 cells
appear significantly more sensitive than leiomyosarcoma SK-UT-1
cells. The potency of nilotinib in these STS cells cannot be
explained by the currently declared mechanism of action of this
drug, namely inhibition of the catalytic activity of BCR-ABL1,
KIT and PDGFR-a/b, because the concentration of nilotinib
required to inhibit these TKs in cellular models is in the
nanomolar range [32,33]. This idea is strengthened by the fact
that imatinib, at clinically achievable plasma concentrations of 5–
10 mM [23] decreased cell viability only between 12–19% (Fig. 1D
and Fig. 2B). Even if indirect, our results suggest that novel
mechanisms may be involved, such as inhibition of other tyrosine
or non-tyrosine kinases. In this context, suppression of prolifera-
tion by imatinib and nilotinib correlated with their capability to
down-regulate AKT and mitogen-activated protein kinases
Figure 7. Nilotinib inhibited MRP-1 activity in human STS cells. Intracellular 5(6)-CFDA fluorescence was estimated by flow cytometry in
synovial sarcoma SW982 and leiomyosarcoma SK-UT-1 cells after 2 h treatment with vehicle (V), imatinib (1–10 mM), nilotinib (1–10 mM) or
probenecid (250 mM). Left, Median of intracellular CFDA fluorescence in the absence or presence of TK inhibitors normalized to vehicle-treated cells
(taken as 100%). Each column represents mean 6 SEM of three independent experiments. Right, Representative flow cytometry analysis of the
intracellular CFDA fluorescence in the absence (vehicle) or presence of imatinib (10 mM) or nilotinib (10 mM) detected with excitation at 488 nm and
emission at 530 nm. T0 was the intracellular CFDA fluorescence measured at t=0.
***P,0.001 versus vehicle-treated cells.
doi:10.1371/journal.pone.0037735.g007
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MAPK, promote growth factor-mediated proliferation, survival
and resistance to apoptosis in STS, including synovial sarcoma.
Consequently, inhibition of MEK/ERK and p38 MAPK is able to
suppress proliferation in several synovial sarcoma cell lines,
including SW982 cells [34,35]. In line with the observed effect on
cell growth, nilotinib but not imatinib fully blocked basal and FBS-
induced ERK1 and p38 MAPK activation in SW982 cells.
Although this effect might be mediated through blockade of
upstream TK receptor signaling, another plausible explanation
would be a direct inhibitory interaction between nilotinib and
ATP-dependent p38 MAPK. In support of this hypothesis, kinase
binding assays have demonstrated substantial binding affinity of
nilotinib to p38 MAPK, which translated into potent inhibition of
the catalytic activity of p38 MAPK in enzymatic assays [33].
Furthermore, nilotinib is more lipophilic and relatively less
protonated at physiologic pH than imatinib [27,36], thus,
facilitating its plasma membrane passage and accessibility of
intracellular interaction partners. For these reasons, it is conceiv-
able that p38 MAPK may be a further important molecular target
of nilotinib, in particular with respect to synovial sarcoma cells.
Besides contributing to aberrant cell proliferation, p38 MAPK
activation also participates in the development of MDR by
modulating the activity and expression of the P-gp protein
[24,25,37]. P-gp and MRP-1 proteins belong to a large family of
ATP-dependent transporters located in the plasma membrane,
which extrude a large variety of compounds, including chemo-
therapeutic agents, out of the cells, thereby decreasing their
intracellular concentrations and consequently reducing their
pharmacological efficacy. Clinical chemotherapy is often counter-
acted by MDR in which overexpression of these proteins in tumor
cells is frequently the prevailing antitumoral resistance mechanism
[38]. Accordingly, in our study synovial sarcoma SW982 cells also
quickly developed this typical feature of MDR, i.e. the induction of
P-gp expression in response to DXR treatment (72 h) (Fig. 8A). In
this experimental set nilotinib prevented DXR-induced MDR
through inhibition of P-gp and MRP-1 activity (Fig. 6 and 7) and
cellular up-regulation of P-gp, which was to be expected because
of the detected blockade of p38 MAPK activation by nilotinib
(Fig. 8B). Consequently, nilotinib increased the accumulation of
DXR inside STS cells (Fig. 5) and enhanced its antiproliferative
and apoptotic effects (Fig. 1 and 2), which was further confirmed
by an enhancement of DXR-induced cleavage of several caspases
(caspase 8, 3 and 7) and fragmentation of PARP. Importantly,
STS cells relatively quickly regained their neoplastic rate of
Figure 8. Nilotinib down-regulated basal P-gp levels and p38
MAPK phosphorylation and fully blocked both DXR-induced
up-regulation of P-gp levels and p38 MAPK phosphorylation.
Sub-confluent synovial sarcoma SW982 cells were treated for 72 h with
vehicle (V), DXR (0.1 mM), nilotinib (10 mM) as single compounds or
combined simultaneously (DXR+Nilotinib). Upper panels show repre-
sentative immunoblots of four independent experiments. A) Columns
represent the ratio of the P-gp to b-actin immunoreactivity or B) the
phosphorylation ratio of p38 MAPK. Each column represents mean 6
SEM of four independent experiments normalized to vehicle-treated
cells (taken as 100%).
*P,0.05 and
**P,0.01 versus vehicle-treated cells.
doi:10.1371/journal.pone.0037735.g008
Table 1. Detection of P-gp and MRP-1 in high-risk locally
advanced soft tissue sarcoma tumors.
Histological type
N6 of
cases P-gp + MRP-1 + Coexpression
Synovial sarcoma 11 8 3 3
Pleomorphic
rabdomyosarcoma
20 1 0
Leiomyosarcoma 4 4 1 1
Pleomorphic liposarcoma 5 3 0 0
Malignant fibrous
histiocytoma
19 7 2 2
Fibrosarcoma 2 0 0 0
Non-classified sarcomas 9 6 1 0
Total cases 52 28 8 6
P-gp and MRP-1 expression was analyzed by immunostaining in a subset of fifty
two high-risk localized STS tumors of limbs or trunk wall, which derived from a
total of three hundred and twenty-eight patients enrolled in a randomized
international trial, as described in the Material and Methods section. P-gp and
MRP-1 expression was evaluated qualitatively: positive or negative.
doi:10.1371/journal.pone.0037735.t001
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sensitization effect of STS cells to DXR induced by nilotinib
was detectable during long time, since cell number was found
strongly reduced even 12 days after withdrawal of both
compounds (Fig. 3). This is in line with the observation that
combination therapy leads to a higher intracellular level of DXR
in tumor cells, which probably requires longer time to be removed
from them. Increased sensitivity to DXR was only detected in STS
cells expressing P-gp and MRP-1, since nilotinib did not alter
intracellular DXR concentration in human fetal lung fibroblasts
(MRC-5) (intracellular DXR fluorescence 1.3-fold in the presence
of 5 mM nilotinib compared to DXR alone). This observation is
consistent with results obtained by Tiwari and colleagues who just
recently reported that nilotinib at 2.5–5 mM reverted P-gp- and
ABCG2-mediated resistance by inhibiting their activity, without
affecting their expression, in human embryonic kidney cells
transfected with these MDR-related proteins [16]. The lower
antiproliferative effect of imatinib and its inability to sensitize STS
cells to DXR may be partially explained by the facts that i)
intracellular uptake of imatinib, but not nilotinib, depends on
expression of organic cationic transporter-1 (OCT-1) influx
protein [36,39], ii) imatinib is a substrate for P-gp provoking a
reduction of its intracellular levels and, iii) in contrast to nilotinib,
imatinib did not show any inhibitory effect on P-gp activity in P-gp
expressing cells at the concentrations examined [40].
Different chemotherapeutics agents have been tested in STS
[41], but this class of solid tumors, particularly synovial sarcoma, is
difficult to treat by chemotherapy. Up to date DXR still remains
the most effective agent and is considered the systemic standard
treatment in metastatic setting throughout the last twenty years
[1]. Nevertheless, neither therapies with DXR alone nor in
combination with ifosfamide have achieved significant improve-
ments in terms of overall survival [42]. In addition to its high
cytotoxicity, some tumors become resistant to this chemothera-
peutic due to development of MDR, mainly characterized by
overexpression of P-gp and MRP-1 [3], to which has been
attributed the failure of cancer therapy in over 90% of patients. In
this context, in a subset of 52 high-risk locally advanced STS
tumor patients derived from a large international study with 328
participants [22] 54% and 15% were positive for P-gp and MRP-1
expression, respectively, with high incidence of P-gp in synovial
sarcoma (73%). Together our results suggest that nilotinib could
be a readily available therapeutic alternative, as single compound
or combined with DXR, for treatment of this type of solid tumors
in general but above all for synovial sarcoma. Although nilotinib at
clinically achievable plasma concentrations of 5 and 10 mM had
only moderate antitumoral effects, combination of nilotinib with
DXR was highly synergistic in both STS cell types. Because of the
wide substrate profile of P-gp in relation to chemotherapeutic
agents [43], it is tempting to speculate that nilotinib could also
enhance the antiproliferative effects of other antitumoral agents
affected by MDR, such as paclitaxel or vinblastine. Noteworthy,
an amplification of the dose-limiting toxic effects of classical
antitumoral agents through co-treatment with TK inhibitors
should not have to be expected. In fact, the clinical viability of
such a combination strategy regarding possible adverse side effects
has already been successfully tested using imatinib plus DXR in
patients with imatinib-resistant GIST [44].
In summary, the present study reveals that the TK inhibitor
nilotinib not only exhibits considerable antiproliferative effects on
STS cells, but also, and in contrast to imatinib, sensitizes them to
DXR by blocking the activity of the MDR-related proteins MRP-
1 and P-gp as well as the DXR-induced expression of P-gp in
synovial sarcoma, the latter most probably through inhibition of
p38 MAPK. These results are of direct clinical relevance as they
provide molecular evidence for the assessment of a novel
chemotherapeutical strategy using nilotinib and DXR as treatment
combination especially in synovial sarcoma. This treatment
approach could ameliorate treatment outcome of patients without
increasing drug toxicity and the official regulatory process to
obtain approval for a clinical study has recently been initiated.
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